NCT03361800View on ClinicalTrials.gov

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

September 18, 2019

Study Completion Date

October 11, 2019

Conditions
Breast CancerInvasive Breast CancerER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions
DRUG

Entinostat

oral drug, 5mg tablet given once weekly x 2 doses

Trial Locations (1)

27599

Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

Syndax Pharmaceuticals
All Listed Sponsors
collaborator

Syndax Pharmaceuticals

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER